ISA2012
Scott Wasserman
Scott Wasserman, MD, FACC is an Executive Medical Director, Amgen Global Development, responsible for clinical development of novel therapeutics forheart failure, hypercholesterolemia, and the emerging cardiovascular pipeline. Previously, on the Cardiovascular Medicine faculty at Stanford University, he was principal investigator on NIH-funded research examining endothelial gene expression and an attending cardiologist at Palo Alto Veterans AdministrationHospital. MD, Magna Cum Laude: Harvard Medical SchoolBS, Magna Cum Laude: Haverford College
- Presenting In
- Effects of AMG145 on Cholesterol Parameters: A Phase 1, Randomized, Double-blind, Placebo controlled Study
